Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Merck To ...

James continues to add to his many milestones in Year 22 with nearly 6,000 more points than any player in history. NBA.com Staff LeBron James hits from long range for 50,000 career points ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...

With 6:44 remaining in the fourth quarter, LeBron James exited the game while the Lakers made progress on their attempted 22-point comeback, but he did not return. He was ruled out for the game ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

March 11 (Reuters) - A federal judge ruled in favor of Merck (MRK.N), opens new tab in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety ...

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...

Another day, another historic milestone in the legendary career of LeBron James. Fresh off being named Western Conference Player of the Month for February, James led the red-hot Los Angeles Lakers ...

SAN FRANCISCO — LeBron James, set to start in the NBA All-Star Game for the 21st consecutive season, removed himself before the game Sunday, saying foot and ankle soreness wouldn’t allow him ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday (March 5, 2025), citing ...